Compare Atlassian Corporation PLC (TEAM) vs Tango Therapeutics Inc. (TNGX) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Atlassian Corporation PLC vs Tango Therapeutics Inc. — how do they compare? Atlassian Corporation PLC trades at $203.6 (market cap $51.81B), while Tango Therapeutics Inc. trades at $22.5 (market cap $3.74B). The key difference: Atlassian Corporation PLC is far larger — about 13.9× Tango Therapeutics Inc.'s market cap, and Atlassian Corporation PLC is trading nearer its 52-week high, Tango Therapeutics Inc. nearer its low. Which is the better fit depends on your goals — on Pluang, investors hold Atlassian Corporation PLC for 65 Days and Tango Therapeutics Inc. for 0 Days on average.
| TEAM | TNGX | |
|---|---|---|
Market Cap | $51.81B | $3.74B |
Volume | 2,082,521 | 3,438,781 |
Sector | Technology | Health |
52-Week High | $208.04 | $32.90 |
52-Week Low | $57.15 | $7.50 |
Typical Hold Time | 65 Days | 0 Days |
Enterprise Value | $51.80B | $2.76B |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Atlassian (TEAM) trades at $208.04, up 0.14% on the day, with strong technical momentum and consistent earnings beats. The stock shows bullish moving average signals despite an overbought RSI near 83. Revenue growth has accelerated from $2.8B in 2022 to $5.2B in 2025, though the company remains unprofitable with a -0.82% net margin. Recent news highlights AI-driven product adoption and cloud migration progress as key growth catalysts.
Outlook remains positive with 70% analyst buy ratings and a $140B addressable market, but high valuations (P/S 8.24, EV/EBITDA 248.18) and persistent losses pose risks. The consensus price target of $197.47 suggests modest downside from current levels, requiring careful monitoring of profitability improvements.
TNGX trades at $22.22, down 8.07% in the last session, reflecting negative investor reaction to recent earnings misses. The stock shows neutral technical signals with key support at $21 and resistance at $23. Fundamentally, the company maintains a high gross margin of 98.25% but faces significant losses with a net income margin of -229.92% and negative cash flow from operations. Recent news highlights institutional buying interest and upcoming clinical trial developments.
Despite strong analyst support with a $45.91 consensus price target (107% upside), TNGX faces substantial execution risks as a clinical-stage biotech. The company's heavy cash burn and lack of profitability require careful monitoring of pipeline progress. Investment appeal hinges on successful drug development outcomes rather than current financial metrics.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
Investor sentiment on Pluang
What Pluang investors did over the last 30 days
About Atlassian Corporation PLC
Atlassian produces software that helps teams work together more efficiently and effectively. The company provides project planning and management software, collaboration tools, and IT help desk solutions. The company operates in four segments: subscriptions (term licenses and cloud agreements), maintenance (annual maintenance contracts that provide support and periodic updates and are generally attached to perpetual license sales), perpetual license (upfront sale for indefinite usage of the software), and other (training, strategic consulting, and revenue from the Atlassian Marketplace app store). Atlassian was founded in 2002 and is headquartered in Sydney.
Read more on TEAM →About Tango Therapeutics Inc.
Tango Therapeutics, Inc. is a clinical-stage biotechnology company focused on precision oncology, developing cancer therapies based on the genetic principle of synthetic lethality, including its PRMT5 inhibitor program.
Read more on TNGX →
